Skip to main content


A study of LY3372689 to assess the safety, tolerability, and efficacy in participants with Alzheimer's disease

Eli Lilly and Company

Information about the drug that will be tested in the study


A capsule taken orally

Is the drug already on the market for another medical condition?


Will all participants receive the same drug?

Participants will be selected at random to either receive one of the following options:

  • A capsule of LY3372689 (low dose)
  • A capsule of LY3372689 (high dose)
  • A capsule of placebo (also called a dummy treatment which is an inactive substance identical in appearance to the drug being tested with no active therapeutic effect).

Neither the participant nor his/her doctor will know if the person is receiving the investigational drug or the placebo.

Information about participating in the trial

What are the researchers trying to find out?

The purpose of the study is to assess the safety, tolerability and effect of LY3372689 in people with early symptomatic Alzheimer's disease.

How long will the treatment last?
  • Participants will receive LY3372689 or placebo for between 76 and 124 weeks
  • The maximum total study duration is 131 weeks (around 2.5 years) and include up to 31 visits to the study center.
What your involvement will entail?

Further information on the procedures, tests and number of visits can be obtained from the study team.

  • During the study, participants will be asked to complete a test that will assess cognition and function (this is a test called iADRS)
  • To complete other tests that will assess their memory, functioning, cognition improvement and activities of daily living (i.e. tests like ADAS-Cog, MMSE, CDR-SB, ADCS-iADL)
  • Participants will be asked to undertake brain scans (PET, MRI) to see changes in biomarkers in the brain.
Who can participate in the study?

To take part in the study, participants must:

  • Be between 60 and 85 years old
  • Have gradual and progressive change in memory function reported by participants or study partner for at least six months
  • Have a score of 0.5 to 1 in the Clinical Dementia Rating-Global Score (CDR) and a score between 22 and 30 in the MMSE test questionnaire test (a test about your memory). This would suggest that the person has an impairment in their memory that is at a very mild stage
  • Have evidence of abnormal accumulation of amyloid in the brain (determined through PET brain scans)
  • Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration.
Who cannot participate in the study?

Exclusion criteria include:

  • Contraindication to brain scans (PET, MRI)
  • Have known allergies to LY3372689, related compounds, or any components of the formulations
  • Participants must not have cancer within the last 5 years
  • Participants must not have history of Hepatitis B or C.

The above list is not exhaustive.

Information for your doctor

EudraCT Number

2021-000170-29 identifier


Study contact information

Link to full text

The information contained in this document is based on information available on public registries (e.g. website) on March 2022.

This document has been reviewed by a member of the European Working Group of People with Dementia.


Alzheimer Europe's Clinical Trials Watch database was developed as part of the 2018 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).

Alzheimer Europe gratefully acknowledges the support of its corporate sponsors for the update and maintenance of the database.